22 June 2021 - 12:00-16:30
13:00 - 14:30
CBW8 EAN/INUS: How to manage neurogenic urogenital and bowel dysfunction by the practicing neurologist
1: Assessment and treatment of bladder dysfunction
Helmut Madersbacher, Rum, Austria
2: Approach to the management of sexual dysfunction
Jalesh Panicker, London, United Kingdom
3: Tips and tricks to the management of bowel dysfunction
Katarina Tudor, Zagreb, Croatia
1: TLOC: listen carefully, look closely
Alessandra Fanciulli, Innsbruck, Austria
2: Syncope, seizure or something else?
Roland Thijs, Heemstede, The Netherlands
3: The dangerous syncope I shouldn’t overlook
Michele Brignole, Lavagna, Italy
SPS13 Gender and Diversity Taskforce: How sex and gender differences may impact research and clinical practice in neurology
1: The impact of sex and gender on the history of global health and care in neurology
Sanjoy Bhattacharya, York, England
2: Sex-related differences in genetic neurological disorders
Christine Klein, Lübeck, Germany
3: Impact of sex and gender on clinical presentation, associated factors, research and management of migraine
Elena Lebedeva, Yekaterinburg, Russian Federation
4: The new perspective in sex and gender-oriented management of neurological disorders
Gennarina Arabia, Catanzaro, Italy
1. Introduction to the European Brain Council (EBC) and the European Brain Research Area (EBRA)
Monica Di Luca, Milano, Italy
2. The shared European Brain Research Agenda (SEBRA)
Kristien Aarts, Brussels, Belgium
3. Accelerating coordination of brain research clusters in Europe
Frédéric Destrebecq, Brussels, Belgium
4. Round Table: EPICLUSTER, BRAINFOOD, TRISOMY21, PREMOS, PSMD
13:00 - 15:00
1: Brain-heart axis and central lesions inducing autonomic dysfunction
Max Hilz, Erlangen, Germany
2: Central ANS dysfunction and brain-heart interactions: from physiological profiling to functional imaging
Jens Jordan, Cologne, Germany
3: Intracranial Pressure and sympathetic activity
Anne Pavy-Le Traon, Toulouse, France
4: Neurocardiac axis: Heart’effects on brain in heart failure
Constandina Arvanitis, Toulouse, France
13:00 - 16:30
1: Introduction; Injectables: Interferon-beta, Glatiramer Acetate
Ron Milo, Ashkelon, Israel
2: Oral therapies: S1P modulators, DMF, Teriflunomide
Celia Oreja-Guevara, Madrid, Spain
3: Monoclonal antibodies: natalizumab, Anti-CD20 mAbs and other B cell-targeted therapies
Paul Friedemann, Berlin, Germany
4: Immune reconstitution therapies: Alemtuzumab, Cladribine, HSCT
Tjalf Ziemssen, Dresden, Germany
1: Stroke Prevention in AF
Maurizio Paciaroni, Perugia, Italy
2: Antiplatelet and Lipid Management
Gian Marco De Marchis, Basel, Switzerland
3: Antithrombotic Therapy in Cerebral vein thrombosis
Diana Aguiar de Sousa, Lisbon, Portugal
4: Secondary Prevention after Intracerebral Haemorrhage
Charlotte Cordonnier, Lille, France
1: What information from imaging does the neurologist need to optimize management, in view of the new WHO classification?
Giulia Berzero, Paris, France
2: How can neuroimaging contribute to the diagnosis of brain tumours: Role of conventional, spectroscopy and perfusion MRI
Ana Ramos, Madrid, Spain
3: Pre- and intraoperative imaging essential to neurosurgery: fMRI, DTI, intraoperative imaging
Tarek Yousry, London, United Kingdom
4: Differentiating tumour recurrence from treatment effect: What should be used and how does it help?
Nicoletta Anzalone, Milan, Italy
1: Precision diagnosis of repeats using long-read sequencing and overview of the common and recently identified repeat expansion disorders
Henry Houlden, London, United Kingdom
2: Clinical features with video examples, management and important red flags in exonic CAG repeat expansion disorders such as SCAs, MD, DRPLA
Sylvia Boesch, Innsbruck, Austria
3: Clinical features with video examples, management and important red flags of intronic repeat disorders such as FRDA, CANVAS
Josef Finsterer, Vienna, Austria
4: Disease mechanisms, therapeutic targets and current trials in repeat expansion disorders
Andrea Cortese, Pavia, Italy
15:00 - 16:30
CON4 EAN/MDS-ES Challenges in translational neurosciences & Treatment of severe forms of multiple sclerosis
1: Are Stem Cells Ready for Clinical Use in Movement Disorders – Yes
TBA
2: Are Stem Cells Ready for Clinical Use in Movement Disorders – No
Joaquim Ferreira, Lisbon, Portugal
3: Autologous hematopoietic stem cell transplantation is the most effective therapy for severe forms of multiple sclerosis
Joachim Burman, Uppsala, Sweden
4: In severe forms of multiple sclerosis we have approved treatments that are very effective with a acceptable safety profile
Ludwig Kappos, Basel, Switzerland
Key
CBW = Case-based Workshop
CDS = Career Development Session
CONT = Controversy Session
FW = Focused Workshop
IAS = Interactive Session
PL = Practical Lesson (Formerly HoC)
SPS = Special Session
SYMP = Plenary Symposia & Symposia
TC = Teaching Course